Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 3 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.

Cangrelor a potential treatment for PCI patients unable to take oral meds

18 Mar 2019

Patients undergoing urgent/emergent percutaneous coronary intervention (PCI) and unable to take oral medications are good candidates for treatment with cangrelor, according to a new meta-analysis.

A pooled analysis of three clinical trials, resulting in a cumulative sample of 24,910 patients, showed that after 48 hours, cangrelor reduced the odds of the primary composite outcome (death, myocardial infarction, ischaemia-driven revascularization or stent thrombosis) by 19 percent (3.8 percent for cangrelor vs 4.7 percent for control; odds ratio [OR], 0.81; 95 percent CI, 0.71–0.91; p=0.007).

Similarly, cangrelor decreased the risk of the secondary outcome of stent thrombosis (OR, 0.59; 0.43–0.80; p=0.0008) and of the secondary composite outcome of death, myocardial infarction and ischaemia-driven revascularization (OR, 0.81; 0.71–0.92; p=0.0014).

The same was true for the risk of the composite of death, Q-wave myocardial infarction and stent thrombosis (OR, 0.63; 0.49–0.81; p=0.0002).

Taking each component of the primary composite outcome independently, cangrelor similarly resulted in significantly reduced odds of ischaemia-driven revascularization (OR, 0.71; 0.52–0.98; p=0.0363) and myocardial infarction (OR, 0.85; 0.74–0.97; p=0.0182).

In contrast, while the death count was lower in those who were on cangrelor medication (0.3 percent vs 0.4 percent), there was no significant difference in risk (OR, 0.73; 0.47–1.15; p=0.1694).

Cangrelor was also relatively safe and well-tolerated, despite a potential side-effect of over-inhibition of the platelet P2Y12 pathway, said researchers. The clinical benefits associated with cangrelor was not hampered by increased risks of severe bleeding and moderate bleeding, or the need for blood transfusion.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 3 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.